biostudies-literatureUnknown23Kwag E<h4>Background</h4>Lung cancer, especially non-small cell lung cancer (NSCLC), poses a significant health challenge globally due to its high mortality. Afatinib, a second-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), has shown superior efficacy over traditional chemotherapy in NSCLC treatment. However, issues like secondary resistance and adverse effects call for alternative therapies. HAD-B1, comprising 4 herbal medicines, has shown promise in lung cancer treatment in both preclinical and clinical settings. This study assesses the combination of HAD-B1 and Afatinib in advanced NSCLC patients to potentially improve outcomes by addressing the limitations of current EGFR-TKI therapies.<h4>Method</h4>A randomized, open-label trial evaluated the efficacy andIntegrative cancer therapies15347354241268231https://www.ebi.ac.uk/biostudies/studies/S-EPMC11301725biostudies-literatureA Randomized, Multi-Center, Open Label Study to Compare the Safety and Efficacy between Afatinib Monotherapy and Combination Therapy with HAD-B1 for the Locally Advanced or Metastatic NSCLC Patients with EGFR Mutations.PMC11301725Kwag ELee SJeong MKBang SHSon JWShin SHHoon Yoon SChoi JYKim SDOak CWoo Lee HYoo HSPark SJKang ICKim SJfalseA Randomized, Multi-Center, Open Label Study to Compare the Safety and Efficacy between Afatinib Monotherapy and Combination Therapy with HAD-B1 for the Locally Advanced or Metastatic NSCLC Patients with EGFR Mutations.<h4>Background</h4>Lung cancer, especially non-small cell lung cancer (NSCLC), poses a significant health challenge globally due to its high mortality. Afatinib, a second-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), has shown superior efficacy over traditional chemotherapy in NSCLC treatment. However, issues like secondary resistance and adverse effects call for alternative therapies. HAD-B1, comprising 4 herbal medicines, has shown promise in lung cancer treatment in both preclinical and clinical settings. This study assesses the combination of HAD-B1 and Afatinib in advanced NSCLC patients to potentially improve outcomes by addressing the limitations of current EGFR-TKI therapies.<h4>Method</h4>A randomized, open-label trial evaluated the efficacy and2024-01-01T00:00:00Z2024 Jan-Dec2025-04-06T03:43:39.022Z2025-04-06T03:43:39.022ZS-EPMC113017253910399110.1177/15347354241268231